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INTRODUCTION 
The allergic response is currently defined as “the result of im-
mune reactions to antigens known as allergens,” characterized 
by the production of specific Immunoglobulin E (IgE) as a con-
sequence of this exposure.1 Nowadays, according to several au-
thors, allergic diseases are going through a stationary or even a 
decreasing phase in terms of prevalence, although the increas-
ing prevalence persists in developing countries, especially 
those in which allergic pathologies were not so common in the 
past.2 An Italian statistic performed in 2005 reports that allergic 
disease is positioned at the third place of chronic pathologies 
with an incidence of 10.9%, with a higher prevalence in females 
(12.9%) vs males (9.6%).3
Allergic disease often deeply affects patients’ quality of life 
and absorbs an important part of health care resources in every 
country. Undeniably, one of the most represented in terms of 
both the number of patients and importance is asthma. Accor-
dini et al.4 stated that in 2010, the annual expenditure for any 
European asthmatic patient was 509 € for controlled asthma 
and 2,281 € for uncontrolled asthma. Not only is asthma one of 
the most prevalent allergic diseases, but it is estimated that 
worldwide, urticaria occurs lifetime with a prevalence of above 
20%,5 and it is also approximated that in 2012, about 8.8 mil-
lions of children reported skin allergies in a 12-month observa-
tion period.6 The high incidence the social burden of these dis-
eases require us to pay more attention to what concerns the di-
agnosis and therapy in these kind of patients. New therapeutic 
approaches have recently been put under investigation. What 
happened to severe uncontrolled asthma with anti-IgE therapy 
has happened to difficultly controlled chronic urticaria also 
with good results in terms of clinical effect7 and safety.8 The im-
portance of precision medicine in other allergic diseases opens 
numerous questions on the need to evaluate the possibility of 
searching several biomarkers for asthma able to predict the re-
sponse to these biological treatments that could be used possi-
bly in the nearest future. 
FROM “ONE SIZE FITS ALL” TO PRECISION MEDICINE 
Allergic and chronic respiratory diseases have an important 
socioeconomic impact and represent an important burden of 
missed or wrong diagnosis. Consequently, adequate diagnosis 
and treatment are unsatisfactory. Precision medicine could 
represent a novel, revolutionary approach,9 ideally capable of 
resolving or at least reducing this burden, implementing physi-
cians’ awareness of these critical issues.1
The “one size fits all” principle on which asthma therapy was 
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based on is radically changing for several years. Actually, one 
size does not fit all. Atopy’s therapy is moving from blockbust-
ers to a phenotype/endotype-driven precision medicine, cur-
rently based on monoclonal antibodies directed against specif-
ic and selected cytokines/interleukins involved in airway re-
modeling and inflammation in chronic severe asthma and at 
the base of several other allergic pathologies. This change in 
route is even deeper than thought before, implying a transition 
from general practitioners, who traditionally treated these dis-
eases, to specialists.10 In fact, patients eligible for monoclonal 
antibodies follow a narrow therapeutic path: specialists are al-
lowed to administer biological drugs, whereas general practi-
tioners take care of the classical management of allergic diseas-
es, as it actually is the case for other medical specialties like on-
cology or rheumatology.
A few years ago, we described a “target medicine like” ap-
proach called “the magic bullets which seek their own targets” 
starting from omalizumab, the first and at that time unique bio-
logic available.11 Conceptually, we described the same process 
of the “Personalized Medicine” targeting with the biologic the 
mechanism of the diseases, as predicted by the immunologist 
Paul Ehrlich one century ago.12
The definition of Precision Medicine given by Passalacqua et 
al.13 could be reassumed as a “structural model aimed at cus-
tomizing healthcare, with medical decisions and products tai-
lored on an individual patient at a highly detailed level.” Preci-
sion medicine’s mantra could be summarized with “prescribing 
the optimal treatment to the right patient,” since no other aller-
gy treatment, excluding possibly monoclonal antibodies, has 
these specific characteristics (Fig. 1).14
Allergen immunotherapy (AIT) represents an optimal model of 
tailored therapies because etiological agents responsible for the 
symptomatological cortege are described at a molecular level. 
Focusing on asthma, traditional anti-asthma therapy was 
based on bronchospasm-relieving (beta-2-agonists) and anti-
inflammatory drugs (corticosteroids) to control symptoms and 
reduce inflammation.15 The reason why we are now moving 
from non-specific drugs to monoclonal antibodies is the fact 
that whereas most people are adequately controlled in their pa-
thology, many asthmatic people still present an uncontrolled 
symptomatic asthma despite the evidence provided by interna-
tional guidelines and maximal therapy.
Hence, this has been necessary to expand our knowledge on 
the physiopathological bases of asthma, rhinitis, and other al-
lergic pathologies and brought to unveil the path to different 
phenotypes of the same disease, forcing to reconsider allergic 
diseases as multifaceted, not static, and invariable entities that 
could benefit from precision medicine. 
Deeping our knowledge about TH2 inflammation and TH2 
cytokines/interleukins permitted us to develop alternative 
treatment strategies based on intervening directly on the mole-
cules responsible for the pathogenesis of allergic diseases and 
establishing the bases for molecularly targeted therapies. 
At the present days, omalizumab, a humanized monoclonal 
antibody directed to circulating IgE, is the only targeted mono-
clonal antibody approved in severe uncontrolled asthma and 
chronic urticaria treatment.
FIRST TARGETED DRUGS IN ASTHMA: OMALIZUMAB 
AND MEPOLIZUMAB 
In the recent years, a new approach in asthma therapy is 
catching on, trying to match the right treatment to a specific 
mechanism of disease. Several studies have been conducted to 
master asthma physiopathology, defining the specific charac-
teristics of asthma phenotypes, and finding each ideally appro-
priate therapy. Nowadays, the majority of new anti-allergic bio-
logic drugs have not been approved yet for routine use, and fur-
ther studies and clinical trials are necessary before they could 
be routinely used.
The first biological target identified in allergic disease was IgE, 
and the first targeted biologic drug, actually the only one avail-
able for routine use, is omalizumab, a humanized, murine-de-
rived, IgG1 monoclonal antibody which is presently approved 
only in severe asthma and chronic urticaria. Omalizumab 
binds to circulating IgE in the Cε3 region hindering their link to 
their receptors FcƐRI and FcƐRII on basophils and mast cell 
membrane, and therefore this avoids degranulation and release 
of allergic inflammation mediators.16
Several studies on the efficacy and safety of omalizumab 
showed a reduction in allergens’ effect on the airways,17 a better 
control of asthma symptoms18 and a significant reduction in the 
number of exacerbations,19 even in subjects poorly responsive 
to maximal therapies.20 Other studies also showed significant 
benefits in allergic asthmatic children21 and a significant reduc-
tion in systemic corticosteroid dosage in subjects with refracto-
Fig. 1. Evolution of treatment in asthma, from a therapy applicable to any pa-
tients to a precision medicine.
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ry disease.22 Omalizumab’s treatment inclusion criteria for asth-
matic patients, adults, and children (6-12 years old) are persis-
tent severe asthma for more than 12 months not adequately 
controlled with high doses of ICS and (long acting beta 2 ago-
nists (LABAs), evidence of the sensitization to a perennial aller-
gen at by detection of specific IgE or skin tests, incomplete con-
trol of respiratory symptoms, high levels of serum IgE, and re-
duced baseline pulmonary function (FEV1<80%).23 Omali-
zumab represents the first and only example of a drug dedicat-
ed to a specific subtype of asthmatic patients and can be con-
sidered the first tile of asthma target therapy’s articulated mosa-
ic. However, some other interesting data seem to reveal a con-
nection between omalizumab responders and periostin lev-
els,24 similar to anti-IL-13 drugs, showing that some mecha-
nisms still have to be clarified. 
In the literature, there are also some off-label uses in several 
diseases in which IgE actually plays an important role in deter-
mining their pathogenesis, such as allergic rhinitis, atopic der-
matitis, anaphylasix, food and drug allergy, eosinophilic granu-
lomatosis with polyangioitis (Churg-Strauss syndrome), eosin-
ophilic pneumonia, allergic bronchopulmonary aspergillosis, 
larynx angioedema, skin diseases, and ocular/ear disorders. 
The evidence of clinical efficacy is still too weak, but they are 
noteworthy. 
The first clinical trial on the efficacy and safety of omalizumab 
goes back to 2001. 
The food and Drug Administration (FDA) approved omali-
zumab in 2003 for treating patients aged 12 years and older suf-
fering from moderate to severe allergic asthma. Moreover, 
omalizumab has recently been approved in chronic urticaria 
treatment strategies. At the present days, omalizumab is soon 
going off patent, opening the drug market to biosimilars, and 
shortly 2 other anti-IgE monoclonal antibodies, quilizumab 
and ligelizumab, will be available.25,26 
If the light of the research has immediately been pointed at 
IgE as the keystone of the allergic response since the beginning 
of asthmatic phenotype characterization, the role of eosino-
phils and the role of IL-5 in their maturation, recruiting, and 
survival processes establishes another pillar of today’s develop-
ing target therapy: anti-IL-5 biological drugs and eosinophil 
count as biomarker. 
Mepolizumab was the first anti-IL-5 drug tested and its con-
nection with eosinophil cells quickly emerged from clinical 
studies. One of the first clinical trials showed poor efficacy on 
reducing asthma symptoms or increasing pulmonary func-
tion.27 However, further trials revealed the bias behind these re-
sults and gave more positive findings. In the first studies, there 
was a lack in selection of patients with high count of eosino-
phils. Other studies successfully reached this objective, collect-
ing very interesting data and demonstrating, in a population of 
asthmatic patients with high sputum/blood eosinophil count, a 
significant reduction in acute exacerbations frequency, a drop 
in eosinophil count, and a significant reduction in systemic cor-
ticosteroids dosage.28,29 Such findings were very relevant, high-
lighting the evident connection between a targeted drug and an 
easy-to-evaluate biomarker, potentially leading to a really effec-
tive targeted therapy for some asthmatic patients. As eosino-
phils are also involved in other diseases than asthma, related 
trials were subsequently performed. Studies in patients with 
Churg-Strauss disease and with hypereosinophilic syndrome 
were conducted, showing good clinical results.30,31 Even in nasal 
polyposis, mepolizumab showed a good efficacy, with a signifi-
cant reduction in polyp size,32 and similar good results were ob-
tained in patients with eosinophilic esophagitis.33 Conversely, 
although a reduction in eosinophilic count, no clinical benefit 
seems to come from mepolizumab’s use in atopic dermatitis.34 
On the way of blocking the IL-5 pathway, several trials were run 
to evaluate the clinical efficacy and safety of reslizumab, anoth-
er anti IL-5 drug, and benralizumab, an anti-IL-5R monoclonal 
antibody. A couple of studies were undertaken to evaluate resli-
zumab’s efficacy and safety on OCS-controlled, hypereosino-
philic asthmatic patients and showed a better control of disease 
exacerbation rate in the treated group versus the placebo popu-
lation.35 Similar results were achieved in benralizumab’s clini-
cal trials which also showed a benefit in pulmonary function 
and a reduction in symptoms, with a tight correlation with eo-
sinophil count.36 Other trials demonstrated a cell-mediated cy-
totoxicity against bone marrow eosinophil’s immature progeni-
tors, “opsonized” by benralizumab.37 About the other eosino-
phil-related diseases, a trial on children and adolescent pa-
tients with eosinophilic esophagitis seemed to show a signifi-
cant reduction in intraepithelial eosinophilic granulocytes, but 
failed to show a significant benefit in symptomatology versus 
placebo.38 Reslizumab was also significantly able to reduce na-
sal polyp size, with a correlation between efficacy and nasal 
IL-5 levels.39 A trial conducted on patients affected by COPD, 
characterized by high eosinophil count, failed to demonstrate 
clinical improvement, even if a not statistically significant bene-
fit in FEV1 and specific questionnaires in patients with blood 
eosinophil >200 cells/mcL seemed to leave an open door for 
further similar studies.40
Unfortunately, nowadays none of anti-IL-5 monoclonal anti-
bodies can be used yet for routine clinical use, although mepo-
lizumab has already been approved by the EMA and the FDA 
and could probably be available in the future.41 
BIOMARKERS AS ESSENTIAL ADJUVANTS IN 
THERAPEUTIC STRATEGY CHOICE 
Several studies have recently underlined that asthma is a 
complex disease with different clusters of symptoms. Since dif-
ferent pathophysiological mechanisms are involved in the dis-
ease development, a single therapy cannot be applied to all pa-
tients.42 Uncertainty remains on why only some patients’ phe-
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notypes and endotypes show an encouraging response to bio-
logical treatments. However, the use of biomarkers specific for 
each phenotype/endotype of asthma could help select patients 
eligible for determinate treatments, for whom a positive re-
sponse could be expected from the utilization of monoclonal 
antibodies.
For these reasons, it is a clear need to find valid biomarkers for 
stratifying patients and to establish appropriate personalized 
therapy. According to the NIH Biomarkers Definitions Working 
Group, a biomarker could be defined as “a characteristic that is 
objectively measured and evaluated as an indicator of normal 
biological processes, pathogenic processes, or pharmacologic 
responses to therapeutic intervention.” 
An ideal biomarker is low-invasive, specific, sensitive, simple-
to-obtain, cheap, and highly reproducible; moreover, it should 
be related to clinical features and not influenced by other dis-
eases.43,44
Various pro-inflammatory stimuli are able to induce nitric ox-
ide (NO) by bronchial epithelial cells. Increased fractional ex-
haled nitric oxide (FeNO) is associated with eosinophilic in-
flammation, poor disease control, and aspirin-induced asthma. 
On the other hand, NO is reduced in patients with non-atopic 
asthma or neutrophilic inflammation, and obese patients.45
FeNO is non-invasive, simple-to-obtain, and highly reproduc-
ible. FeNO measurement can be used to predict steroid re-
sponse in patients with eosinophilic inflammation. Moreover, 
FeNO is more influenced by asthma control than by severity, 
and this peculiarity makes this test useful for disease manage-
ment.46 Several attempts have been made to standardize FeNO 
measurement and to develop guidelines that could help the 
physicians in clinical practice. Guidelines suggest the following 
cutoff points: low FeNO <25 ppb (<20 ppb in children), inter-
mediate FENO between 25 and 50 ppb in adults (20-35 ppb in 
children), and high FENO >50 ppb in adults ( >35 ppb in chil-
dren).47 
FeNO is influenced by factors not directly related to asthma, 
such as age, weight, gender, rhinitis, and smoking; moreover, it 
is an expensive technology and not all centers can afford it. An-
other FeNO disadvantage is the lack of association with some 
asthma phenotypes, for example neutrophilic inflammation. 
Although a unique marker of asthma does not exist at present, 
FeNO could be used in association with clinical evaluation, 
sputum analysis, and pulmonary function tests to draw a cor-
rect management plan of asthma therapy and at follow up.48
Exhaled breath condensate (EBC) is another noninvasive 
technique that could be used to evaluate pulmonary inflamma-
tion. EBC is obtained by condensation of exhaled aerosols. EBC 
permits us to obtain various markers that correlate with treat-
ment’s response and asthma severity; moreover, EBC is simple 
and can also be obtained from children without train. In asth-
matic patients, EBC analysis shows increased concentrations of 
endogenous reactive oxygen species (ROS), adenosine, arachi-
donic acid metabolites, nitrogen reactive products, ammonia, 
and pro-inflammatory cytokines.49
Unfortunately, EBC analysis has not been standardized yet, 
and we have no guidelines. Furthermore, another critical issue 
is that EBC results are influenced by smoking, alcohol, infec-
tions, exercise, and other factors that should be taken into 
count.50
Periostin is a matricellular protein that binds to several other 
proteins, such as collagen, fibronectin, and tenascin-C, with an 
important role in the maintenance of inflammatory processes. 
Sidhu et al.51 demonstrated that periostin is produced by epi-
thelial lung cells by the stummulation of IL4 and IL-13, and it 
could be suppressed with the use of corticosteroids. This means 
that although periostin may also be present at non-physiologi-
cal quantities in other diseases, it could be used as a biomarker 
in some forms of severe asthma.51 
The characteristics that make periostin a good biomarker are 
its facility in passing from inflamed tissues to the blood and the 
low serum basal level in physiological conditions.52 
A study conducted by Corren et al.53 demonstrated that high 
serum periostin levels are associated with a greater response to 
lebrikizumab, a humanized monoclonal antibody that blocks 
IL13 reducing the release of signaling molecules and prevents 
airway remodeling. The variables taken into count to evaluate 
the response to therapy were the changes in pulmonary func-
tion and the lowering of exacerbations rate.53 
Nevertheless, there are some critical issues that actually limit 
the use of periostin as a biomarker for asthma. Periostin levels 
rise in several diseases which have an increased basal cellular 
activity, such as cancers with metastatic spread and several oth-
er ones, highlighting the role of clinicians in properly evaluating 
comorbidities. Moreover, at the present days, we do not achieve 
any standardization of periostin measurement, and cutoff val-
ues have not yet been established (Fig. 2).
Eosinophils play a central role in asthma, being involved in 
the development of allergic processes and in the maintenance 
of inflammatory phenomena. Eosinophil are recruited by vari-
ous proteins secreted by epithelial cells; eotaxin1 (CCL-11) is 
one of the most potent chemoattractants and a correlation has 
been demonstrated between CCL-11 and asthma severity.54 
Eosinophil count can be considered a good marker of asthma 
as it is related to clinical manifestation. A previous analysis con-
ducted has demonstrated the reduction in the number of eo-
sinophil count in the peripheral blood of asthmatic patients un-
der treatment with omalizumab. High eosinophil counts in 
sputum might be related to the thickening of the reticular base-
ment membrane, showing that the number of eosinophil can 
go hand in hand with airway remodeling.55
Though eosinophil count is a simple, non-invasive test, there 
is a weak correlation between sputum eosinophils and re-
sponse to treatment with mepolizumab.56
Eosinophil count alone is not a complete biomarker; in order 
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to better follow the trends of asthma, it could be useful to asso-
ciate eosinophil count with other biomarkers, such as periostin, 
FeNO, and pulmonary function tests.
In conclusion, there is no single biomarker valid to be used 
alone as the gold standard. A biomarker capable of predicting 
airway inflammation degree may not be valid for predicting the 
response to therapy. It is therefore necessary to the combined 
use of biomarkers to improve asthma management strategies.56
TARGET DRUGS IN ANGIOEDEMA
Angioedema is a localized and self-limiting edema of the sub-
cutaneous or submucosal tissue, due to a temporary increase 
in vascular permeability caused by the release of different vaso-
active mediators.57 Organs involved include the skin, orophar-
ynx, upper respiratory airways, and gastrointestinal tract. Dif-
ferent types of acquired and hereditary angioedema are now 
identified. Acquired angioedema can be secondary or a side ef-
fect in approximately 1% of patients treated with angiotensin-
converting enzyme inhibitors (ACE-I) and is a common cause 
of hospitalization for allergic disease after asthma.58,59
Idiopathic acquired angioedema can be histaminergic (IH-
AAE) or non-histaminergic (INH-AAE). Angioedema with C1-
INH deficiency can be acquired (no family history and onset af-
ter 40 years) or hereditary in association with a genetic C1-INH 
deficiency. Hereditary angioedema due to C1-INH deficiency 
(C1-INH-HAE) is an autosomal dominant condition with preva-
lence of approximately 1.5/100.000 inhabitants.60,61 HAE is 
caused by the overproduction of bradykinin and the activation 
of the bradykinin β-2 receptor.61 Recent evidence suggests that 
VEGF-A, previously known as Vascular Permeability Factor, 
could contribute to increased vascular permeability in HAE pa-
tients.62
C1-INH-HAE is manifested by recurrent, localized subcutane-
ous, or submucosal edema lasting 2-7 days. The clinical expres-
sion is highly variable among patients. Patients with C1-INH 
present with low C4, and measurement of C4 levels is used to 
screen C1-INH-HAE because it is decreased between attacks 
and can be only exceptionally normal.63 Diagnosis is confirmed 
by plasma levels of C1-INH below 50% of the normal value. 
Two phenotypic variants of C1-INH-HAE have been described: 
85% of cases are characterized by low antigenic and functional 
levels of C1-INH; 15% of patients have normal quantitative lev-
els of C1-INH and diagnosis requires measurement of C1-INH 
activity in plasma. Edema of the larynx is the most fearsome 
feature of this disorder and can be life-threatening.64
HAE-affected individuals carry a mutation in the C1-INH 
gene. C1-INH maps on chromosome 11q12-q13.1; it is ar-
ranged in 8 exons, the first one containing 38 bp of non-coding 
sequence and the second having a 22 bp-long signal peptide 
before the first methionine.65 More than 300 C1-INH deficien-
cy-causing mutations leading to failure in production or activi-
ty of C1-INH protein have been identified. This explains the 
phenotypic heterogeneity of hereditary angioedema. Approxi-
mately 25%-30% of these mutations occur as de novo events.66 
The phenotype of HAE is extremely variable and includes dif-
ferent degrees of severity and number of attacks, and their lo-
calization. Interestingly, there does not seem to be a correlation 
between gene mutations, C1-INH levels, and phenotypes in pa-
tients with HAE.65,67 The care of patients with HAE is neither op-
timal nor uniform in Europe,68,69 Canada,70 and worldwide. 
Management of HAE can also be divided into various ap-
proaches due to the heterogeneity of the disorders. The aim of 
treatment of acute attacks, also referred to as “on-demand ther-
apy,” is to minimize their severity, including potentially fatal 
upper airway edema, and associated with impaired quality of 
life (QoL). The heterogeneity of the phenotype of HAE therapy 
should be personalized.
Acute treatment includes plasma-derived C1 inhibitor (pdC1-
INH) (Berinert→, Cinryze) recombinant human C1-INH (rhC1-
INH, Ruconest→),71 and antagonist of bradykinin β2-receptor 
Icatibant (Firazyr→),72 which are all acceptable options for acute 
treatment. Icatibant may be particularly useful in enabling self-
administration as intravenous access is not necessary. The in-
hibitors pdC1-INH and rhC1-INH are administered intrave-
nously. Regular profilactic treatment with C1-INH may be nec-
essary for patients having 2 or more attacks per week. Recent ev-
idence suggests that self-administration of C1-INH is emerging 
as an effective treatment to improve clinical outcomes and re-
duce costs in HAE.73 Ecallantide (Kalbitor→, Dyax Corp) is a 
60-amino acid recombinant protein approved by the FDA, but 
not by the EMA, as s.c. injection in the treatment of acute attacks 
of angioedema.74 Due to the uncommon risks of anaphylaxis, 
Ecallantide must be administered by healthcare professionals.
In patients with frequent attacks or on demand therapy is in-
Fig. 2. Progression of personalized medicine and the necessity to expand the re-
search to find molecular biomarkers able to predict patient’s response to therapy.
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adequate to achieve control of the disease, long-term prophy-
laxis should be considered. Similar to the treatment of acute at-
tacks, the long-term prophylaxis of angioedema must be per-
sonalized. Attenuated androgens are effective in long-term pro-
phylaxis for most people. Stanozolol (Winstrol®, Winthrop, 
Bridgewater, NJ) can be administered orally (2 mg/or less). Da-
nazol (Danatrol®, Sanophi-Aventis, Paris, Fr) can also be ad-
ministered orally (200 mg/or less). Stanozol® and Danazol®, 
particularly at high doses, carry a potential cardiovascular risk.75 
In addition, these drugs should not be used in children and 
pregnant patients. Risk-benefit balance of long-term adminis-
tration of androgens should always be carefully evaluated, and 
treatment should be individualized according to individual risk 
factors, response to treatment, contraindications, and possible 
adverse events.
Finally, because HAE is a rare disease, patient information 
and support should be comprehensive and consistent. Psycho-
logical support should be provided by specialists and health-
care professionals.76
Chronic Spontaneous (idiopathic) Urticaria (CSU) is charac-
terized by itchy wheals and flare reactions, angioedema, or 
both for greater than 6 weeks.77 CSU has been estimated to af-
fect approximately 0.5%-1% of the general population. Antihis-
tamines are the first-line therapy for acute and chronic urticar-
ia. Unfortunately, approximately 50% of patients to respond 
CSU fail with this therapy and require additional medications. 
Some of these patients have IgE autoantibodies against auto-
antigens, whereas in the majority of cases the nature of the ab-
normalities cannot be identified.78 Two phase II and phase III 
multicenter, randomized, placebo-controlled clinical trials7,8,79 
have established that omalizumab is safe and efficacious for 
treating recalcitrant patients with CSU that cannot be ade-
quately treated with conventional therapy. Different from asth-
ma80 and EGPA,81 omalizumab rapidly acts in patients with 
CSU. The mechanisms of action of omalizumab in chronic urti-
caria are largely unknown. It has been suggested that omali-
zumab blocks IgE antibodies with cross-reactivity to low con-
centrations of self-antigens.78 
FUTURE PERSPECTIVES (OFF-LABEL USES)
Off-label use of omalizumab in allergic b disease showed in-
teresting results. These type of studies can enlarge the treat-
ment possibilities of various disease, which are uncontrolled, 
partially controlled, or controlled at the cost of relevant side ef-
fects, maybe allowing a progressive enlargement of official clin-
ical indications as it happened for chronic urticaria. Although 
its IgE-binding activity, omalizumab has also been tested even 
in subjects with non-allergic asthma, anecdotally showing good 
results in long-term treatment,82 with significant reductions in 
exacerbation frequency and improvements in pulmonary func-
tions.83 A study conducted on 10 patients affected by occupa-
tional asthma and treated with omalizumab showed a reduc-
tion in exacerbation rate and a decrease in corticosteroids (both 
inhaled and systemic) dose.84 Actual knowledge about the effi-
cacy of anti-IgE therapy in allergic bronchopulmonary aspergil-
losis is still insufficient as significant benefits shown in some 
studies85 were not confirmed in other clinical trials.86 Chronic 
urticaria is not the only dermatologic disease in which omali-
zumab’s efficacy and security have been explored. Hotze et al.87 
performed a trial of 20 patients affected by atopic dermatitis 
and demonstrated a connection between the absence of a pri-
mary deficit in mechanic cutaneous barrier, high levels of some 
glicerophospholipides, and a good response to omalizumab. 
Nevertheless, they concluded that despite the positive results 
obtained with omalizumab, further investigations are neces-
sary to demonstrate anti-IgE therapy’s efficacy in atopic derma-
titis. Interesting results also came from the application of omal-
izumab in bullous pemphigoid, with a significant decrease in 
the eosinophilia that tipically accompanied this cutaneous dis-
ease.88 In association with desensitizing immunotherapy, omal-
izumab showed clinical efficacy in reducing symptoms in poly-
sensitized children and adolescents with seasonal allergic rhi-
nitis,89 showing discordant results in patients with chronic rhi-
nitis and nasal polyposis,90,91 both entities which are hypotheti-
cally present in asthmatic patients. 
Eosinophilic otitis media (EOM) is an intractable chronic oti-
tis characterized by highly viscous effusion that contains plenty 
of eosinophils, IgE, eosinophil cationic protein, and IL-5.92 EOM 
has frequently been associated with asthma and shown a good 
response to omalizumab93 together with an interesting reduc-
tion in eosinophil’s proteins in middle ear fluids.94 The efficacy 
of association of omalizumab and immunotherapy in allergic 
patients was also demonstrated in another study,95 in which the 
addition of anti-IgE allowed for escalation of therapeutic aller-
gen doses. Similar trials showed the same efficacy in associa-
tion with desensitizing therapy in food allergy.96 One of these 
trials showed an interesting link between omalizumab’s onset 
of action and basophil count, opening a possible path to the 
discovery of a new biomarker.97 The scientific literature is full of 
single-patient case reports showing the efficacy of an anti-IgE 
therapy in several other allergic diseases. More extended and 
accurate studies, together with a meticulous analysis of the bio-
chemical basis of these diseases, finalized, to look for new valid 
biomarkers that could lead many of these pathologies actually 
treated with unspecific drugs (i.e., corticosteroids) and to have 
valid target therapies. More knowledge of biomarkers and 
mechanisms understating allergic disease could allow us to 
consider different therapeutic approach from a single drug ap-
proach, to an “articulated therapy” where physicians could use 
a sequence of biological products able to act on different patho-
physiological disease’s steps,98 for instance, omalizumab asso-
ciated by allergen immunotherapy (AIT) (Fig. 3).99
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Writing this paper, maybe for pure curiosity, we conducted a 
medline using the word “allergy” and the name of the principal 
monoclonal antibodies. We decided to restrict the research 
field to clinical trials performed from 2001, year of the first clini-
cal trial on omalizumab, until today. The aim was to have an es-
teem of how many clinical trials have been conducted on the 
application of monoclonal antibodies in allergic diseases’ ther-
apeutic strategies since nowadays. Interestingly, we found that 
151 clinical trials were run involving omalizumab: 21 trials in-
volving mepolizumab, 3 trials regarding reslizumab, 4 trials us-
ing lebrikizumab, 10 trials concerning benralizumab, 2 trials 
about pitrakinra’s use, 1 trial on tralokinumab, and 3 trials on 
dupilumab’s potentially relevant role in severe uncontrolled 
asthma therapy. The first clinical trial performed on a mono-
clonal antibody (omalizumab) goes back to 2001, and after 
more than 15 years, our knowledge on omalizumab and its pos-
sible further applications are still too narrow and have to be en-
larged, possibly including other allergic diseases. Hence, the 
use of the other monoclonal antibodies needs to be further in-
vestigated, our knowledge on their use has to be deepened, and 
other clinical trials have to be performed on allergic subjects 
before we could utilize target therapies in therapeutic treat-
ment strategies.
The application of these issues might possibly reduce the bur-
den of refractory allergic disease that places allergic pathologies 
at the third place of the list of chronic diseases and makes them 
a blackhole of economic resources.
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